ACR Journals On Air
A Noble Goal
Nov 28, 2023
Dr. Brad H Rovin, the first author of a manuscript on Lupus Nephritis treatment, discusses a study on Obenituzumab and its effects on kidney function in Lupus Nephritis patients. The study revealed that Obenituzumab could help preserve kidney function and reduce lupus nephritis flares. The podcast also touches on challenges in conducting clinical trials for Lupus Nephritis and the potential of precision medicine. Additionally, the guest shares their goal of fishing in every country they speak in and their fishing experiences.
39:36
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Obinituzumab, a B-cell targeting agent, demonstrated enhanced B-cell depleting ability and reduced reliance on complement-mediated cytotoxicity, making it a potential treatment option for lupus nephritis.
- Patients receiving Obinituzumab experienced a slower decline in kidney function compared to the placebo group, highlighting its potential to maintain kidney health and improve long-term outcomes for patients.
Deep dives
The Nobility Trial
The podcast discusses the Nobility trial, a phase 2 trial that explored the use of Obinituzumab, a B-cell targeting agent, in treating proliferative lupus nephritis. The trial added Obinituzumab or placebo to standard care therapy and followed patients for two years, allowing for a comprehensive assessment of the drug's effects on kidney function. Obinituzumab, a completely humanized molecule, demonstrated enhanced B-cell depleting ability and reduced reliance on complement-mediated cytotoxicity, making it a potential treatment option for lupus nephritis.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
